CDKN2A and adrenal cortex carcinoma: In addition, CDKN2A expression levels were associated with the prognosis of patients with ACC, COAD, ESCA, HNSCC, KICH, KIRC, KIRP, LGG, LIHC, MESO, PRAD, UCEC, and UVM, at least in disease-specific survival, disease-free survival interval, and progression-free interval (p < 0.05, Fig. 7C, D and 8A–D).